|View printer-friendly version|
LifeMap Sciences’ discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human embryonic stem cells generated by
Human pluripotent stem cells such as human embryonic stem (hES) and induced pluripotent stem (iPS) cells have the important distinction of being the first human cells ever discovered that are capable of indefinite scale-up in the stem cell state, with the potential to then become any of the thousands of different cell types that make up the human body. The discovery of hES cells in the late 1990s led to the emerging field called regenerative medicine. BioTime’s mission is to lead in the commercial application of pluripotent stem cell technology in regenerative medicine by utilizing a number of novel cell manufacturing platforms such as PureStem™ human progenitor cell lines. These hES- or iPS-derived cell lines are relatively pure and scalable lines of cells that allow the industrial scale-up of sufficiently large numbers of cells to be potentially useful in treating a wide array of degenerative diseases including those afflicting an aging population.
Under the collaboration,
The PureStemTM cell lines are a diverse library of purified cell lines representing young cells intermediate in their differentiation between the hES cells and the final, mature cells. Each PureStem™ cell line has a unique gene expression “signature”. This signature is altered in novel ways when a PureStem™ cell line is exposed to different experimental conditions utilizing protein growth and differentiation factors.
The LifeMap Discovery™ platform provides the road map that enables “navigating” each of the PureStem™ cell lines to the desired “destination” of a certain mature cell type for use in treatment. It includes reference gene expression signatures of thousands of embryonic and mature cell types. LifeMap’s scientists match the signatures of PureStem™ cell lines to the cells in its database using tailored bioinformatics computer tools and determine the identity of PureStem™ cell lines before and after they are exposed to various growth and differentiation conditions. In the next step, PureStem™ cell lines that may potentially replace, or rejuvenate, diseased tissues can be identified and later tested for their therapeutic potential for selected diseases.
“LifeMap Sciences, through its online databases such as GeneCards®, MalaCards, and LifeMap Discovery™, as well as its internal research team, has assembled one of the world’s most powerful molecular analysis capabilities,” said
“The BioTime and LifeMap teams collectively believe that this collaboration has the potential to generate a robust pipeline of important stem-cell-based treatments for commonly occurring degenerative diseases,” said
LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on its integrated database suite, the discovery platform for biomedical and stem-cell research. This platform includes GeneCards®, the leading human gene database; LifeMap Discovery™, the database of embryonic development, stem cell research and regenerative medicine; and MalaCards, the human disease database. LifeMap Sciences also markets PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products.
In addition to database offerings, LifeMap Sciences is BioTime’s principal internet marketing subsidiary for research products, including PureStem™ human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™ growth media for progenitor cell lines, and cell differentiation media for non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences utilizes its databases as part of its online marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.
In a therapeutic discovery collaboration with
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
Peter Garcia, 510-521-3390, ext 367
Chief Financial Officer
Judith Segall, 510-521-3390, ext 301